Technology Platform


News Center

Gmax Biopharm International raises USD 78M funding

The financing will help revamp our clinical trials and develop pipeline candidates to produce more innovative medicines for global patients in a much faster speed.

GMAX Zhengzhou Manufacturing Site Breaks Ground

Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.